Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Angiogenesis ; 22(3): 441-455, 2019 08.
Article in English | MEDLINE | ID: mdl-31161471

ABSTRACT

The origin of blood and lymphatic vessels in high-grade serous adenocarcinoma of ovary (HGSOC) is uncertain. We evaluated the potential of cancer stem cells (CSCs) in HGSOC to contribute to their formation. Using spheroids as an in vitro model for CSCs, we have evaluated their role in primary malignant cells (PMCs) in ascites from previously untreated patients with HGSOC and cell lines. Spheroids from PMCs grown under specific conditions showed significantly higher expression of endothelial, pericyte and lymphatic endothelial markers. These endothelial and lymphatic cells formed tube-like structures, showed uptake of Dil-ac-LDL and expressed endothelial nitric oxide synthase confirming their endothelial phenotype. Electron microscopy demonstrated classical Weibel-Palade bodies in differentiated cells. Genetically, CSCs and the differentiated cells had a similar identity. Lineage tracking using green fluorescent protein transfected cancer cells in nude mice confirmed that spheroids grown in stem cell conditions can give rise to all three cells. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor inhibited the differentiation of spheroids to endothelial cells in vitro. These results suggest that CSCs contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary, which can be inhibited.


Subject(s)
Adenocarcinoma/pathology , Lymphangiogenesis , Neoplasms, Cystic, Mucinous, and Serous/pathology , Neoplastic Stem Cells/pathology , Neovascularization, Pathologic/pathology , Ovarian Neoplasms/pathology , Adenocarcinoma/blood supply , Adenocarcinoma/ultrastructure , Ascites/metabolism , Ascites/pathology , Bevacizumab/pharmacology , Bevacizumab/therapeutic use , Biomarkers, Tumor/metabolism , Blood Vessels/pathology , Cell Differentiation/drug effects , Cell Line, Tumor , Endothelial Cells/metabolism , Female , Humans , Neoplasm Proteins/metabolism , Neoplasms, Cystic, Mucinous, and Serous/blood supply , Neoplasms, Cystic, Mucinous, and Serous/ultrastructure , Neoplastic Stem Cells/ultrastructure , Ovarian Neoplasms/blood supply , Ovarian Neoplasms/ultrastructure , Pericytes/pathology , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Vascular Endothelial Growth Factor A/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...